about
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammationTreatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell responseInterleukin-18: a therapeutic target in rheumatoid arthritis?IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cellsExpression and function of Toll-like receptor on T cellsMicroRNA29a regulates IL-33-mediated tissue remodelling in tendon diseaseInterleukin-33 and the function of innate lymphoid cellsIL-33, a potent inducer of adaptive immunity to intestinal nematodesProstaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma productionIL-33 reduces the development of atherosclerosisIL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut.Nitric oxide enhances Th9 cell differentiation and airway inflammation.A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62.ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance.Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMPToll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells.Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice.The role of innate mediators in inflammatory response.IL-15 mediates immune inflammatory hypernociception by triggering a sequential release of IFN-gamma, endothelin, and prostaglandin.Regulation of type 17 helper T-cell function by nitric oxide during inflammationMicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritisLow expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritisIL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival.IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells.A novel negative regulator for IL-1 receptor and Toll-like receptor 4.Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40IL-33 mediates antigen-induced cutaneous and articular hypernociception in miceCytokine networks--towards new therapies for rheumatoid arthritis.IL-33 exacerbates antigen-induced arthritis by activating mast cells.TLR2 is expressed on activated T cells as a costimulatory receptorNitric oxide-induced regulatory T cells inhibit Th17 but not Th1 cell differentiation and function.The cytokine interleukin-33 mediates anaphylactic shock.What can the periodontal community learn from the pathophysiology of rheumatoid arthritis?Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages.IL-33 reduces macrophage foam cell formation.TLR9-independent effects of inhibitory oligonucleotides on macrophage responses to S. typhimurium.IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population.Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain.
P50
Q24309034-66E2BFCF-A601-4FC9-9D17-05BDD142A389Q24675373-20ABC123-AF63-466C-BED1-9BE401310262Q24799490-3827BBDA-3C7B-44F8-B6D2-6C75FDC7434EQ28249077-D958E847-1231-4FF0-A572-EF9CFDB4841EQ28255954-AEFA1919-EC9F-4BF2-9B5D-C9C4BC5D6B72Q28260209-1CC3F044-B8E4-47B8-A571-7DF8BCA9169CQ28266987-C54614ED-F5BD-41D8-A91D-49B67E0AA17EQ28505946-84F4B3C1-C0C9-4063-883B-D0800E9D3FD2Q28586710-72C3FC82-CD79-48BE-B868-07FA51B20A05Q28594104-43B49489-B536-46F2-94D8-1315E27C9049Q33551489-54C84B21-C259-4084-9D87-2B4C39AE31D5Q33574472-4B0F90D3-817F-4C72-BB1F-7DAE6EB0C215Q34037524-BB91874E-1576-4BD8-A6CE-84C9746AE32EQ34220228-3735DBBB-6408-4E20-B425-A09C31FA8C02Q34303629-4AAE9C97-08A2-40C1-BEE0-3753D8B94465Q34415795-E43AF979-0507-4D02-A579-11448CF6053EQ34557118-3E598D19-9912-46BC-A362-B8A03EDFB604Q34626217-6F40D701-9395-470E-A915-7E59B81A6D36Q34636524-69ED64E6-F715-4AFF-A19B-A0706A082BCBQ34687192-3EFA7694-421D-411E-972C-9386CD7EEDCFQ35021942-7B4B4C8C-7D67-469D-A797-A6AF7C59D922Q35091092-28DDA61B-CB06-4E56-89B3-6EE13BD51847Q35134668-314E0743-739C-4DB0-AE86-02421EC3643AQ35402371-52118947-0EE1-4E54-B694-D3FA0B828B28Q35557167-477B1A49-297C-4817-912E-421E52917406Q35976736-20B095E4-3494-4423-9496-3E05487D0CADQ35995103-F0D87CF7-72C6-432D-90CD-6D32DE080635Q36497523-46D4D1FB-D0D7-4601-8CD8-75109F3BBE9CQ36577367-771199F1-40C8-453D-AD5D-D60621FCB75CQ36800502-4DE895A9-78D0-45BE-99C5-C5E60A61EEA0Q36853515-C3267811-FD78-4732-9952-371B8A8BC738Q37202357-36983B4A-63FB-4BFD-B5FA-A22A145D7612Q37238924-C31F06DD-6140-4B64-BACD-EAA6F8014793Q37842638-898E8345-64A2-41F9-A81A-5979293EC5D9Q38293673-99201DE0-6325-49B8-979B-529A68AD6726Q39693915-4BDFE81C-9A90-470A-8E2D-6544733F4E9DQ39910223-2BE231AF-C767-474A-8B75-CF4B247376D3Q40265668-4E610120-711D-461B-B95F-12D3D28DF7BBQ40377079-08FDB74C-C649-4FCC-AC9A-C571D4EEA42BQ41032148-C941DE07-8F6D-4DBB-9A00-03A2ED1F280C
P50
name
Foo Y Liew
@en
type
label
Foo Y Liew
@en
prefLabel
Foo Y Liew
@en